PE20050949A1 - Moleculas de union nogo-a - Google Patents
Moleculas de union nogo-aInfo
- Publication number
- PE20050949A1 PE20050949A1 PE2004000908A PE2004000908A PE20050949A1 PE 20050949 A1 PE20050949 A1 PE 20050949A1 PE 2004000908 A PE2004000908 A PE 2004000908A PE 2004000908 A PE2004000908 A PE 2004000908A PE 20050949 A1 PE20050949 A1 PE 20050949A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr
- seq
- union
- human
- molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA MOLECULA DE UNION QUE ES CAPAZ DE UNIRSE AL POLIPEPTIDO Nogo A HUMANO (SEC ID NO:5), NiG HUMANO (SEC ID NO:7) O NiG-D20 HUMANO (SEC ID NO:24) O Nogo A_342-357 HUMANO (SEC ID NO:6) CON UNA CONSTANTE DE DISOCIACION <1000 nM Y COMPRENDE UN PRIMER SITIO DE UNION DE ANTIGENO COMPRENDIENDO EN SECUENCIA LAS REGIONES HIPERVARIABLES CDR-H1, CDR-H2 Y CDR-H3, DE LAS CUALES UNA DE ESTAS REGIONES SON POR LO MENOS 50% HOMOLOGAS A SUS REGIONES HIPERVARIABLES EQUIVALENTES CDR-H1-3A6 (SEC ID NO:8), CDR-H2-3A6 (SEC ID NO:9) Y DICHA CDR-H3-3A6 (SEC ID NO:10) Y UN SEGUNDO SITIO DE UNION QUE COMPRENDE LAS REGIONES HIPERVARIABLES CDRL-1, CDR-L2 Y CDR-L3, DE LAS CUALES CADA UNA DE SUS REGIONES SON POR LO MENOS 50% EQUIVALENTES A SUS REGIONES HIPERVARIABLES EQUIVALENTES CDR-L1-3A6, CDR-L2-3A6 Y CDR-L3-3A6. TAMBIEN SE REFIERE A UN POLIPEPTIDO QUE CODIFICA DICHA MOLECULA DE UNION; UN VECTOR DE EXPRESION QUE COMPRENDE DICHO POLINUCLEOTIDO; UN SISTEMA DE EXPRESION QUE COMPRENDE UN POLINUCLEOTIDO CAPAZ DE PRODUCIR UNA MOLECULA DE UNION; UNA CELULA HUESPED AISLADA QUE COMPRENDE EL SISTEMA DE EXPRESION Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHA MOLECULA DE UNION, EL CUAL ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON LA REPARACION DE NERVIOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321997.9A GB0321997D0 (en) | 2003-09-19 | 2003-09-19 | Organic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050949A1 true PE20050949A1 (es) | 2005-12-16 |
Family
ID=29266310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000908A PE20050949A1 (es) | 2003-09-19 | 2004-09-17 | Moleculas de union nogo-a |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20090181023A1 (es) |
| EP (3) | EP2423225A3 (es) |
| JP (1) | JP2007527232A (es) |
| KR (1) | KR20060119982A (es) |
| CN (1) | CN1878792A (es) |
| AR (1) | AR045671A1 (es) |
| AU (2) | AU2004274164B2 (es) |
| BR (1) | BRPI0414174B8 (es) |
| CA (1) | CA2538725C (es) |
| CO (1) | CO5680457A2 (es) |
| EC (1) | ECSP066431A (es) |
| GB (1) | GB0321997D0 (es) |
| IL (2) | IL174145A (es) |
| IS (1) | IS8404A (es) |
| MA (1) | MA28088A1 (es) |
| MY (2) | MY161068A (es) |
| NO (1) | NO20061678L (es) |
| NZ (1) | NZ545679A (es) |
| PE (1) | PE20050949A1 (es) |
| RU (1) | RU2380377C2 (es) |
| SG (1) | SG146660A1 (es) |
| TN (1) | TNSN06085A1 (es) |
| TW (1) | TWI372060B (es) |
| WO (1) | WO2005028508A2 (es) |
| ZA (1) | ZA200601842B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1711530T3 (pl) * | 2003-12-22 | 2010-01-29 | Glaxo Group Ltd | Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych |
| SG157418A1 (en) * | 2004-12-01 | 2009-12-29 | Univ Singapore | Nogo a protein fragments as neuronal network- interacting peptides |
| PL1899377T3 (pl) * | 2005-07-05 | 2013-01-31 | Glaxo Group Ltd | Humanizowane przeciwciała specyficzne dla nogo-a i ich zastosowania farmaceutyczne |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| AU2008317724B2 (en) | 2007-11-02 | 2011-06-02 | Novartis Ag | Improved Nogo-A binding molecules and pharmaceutical use thereof |
| US8828390B2 (en) | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
| KR20150036398A (ko) | 2012-07-05 | 2015-04-07 | 글락소 그룹 리미티드 | 근육위축가쪽경화증의 치료에서의 항ｎｏｇｏａ 항체의 최적 투여 섭생 |
| CN113527462B (zh) * | 2020-04-22 | 2023-05-23 | 北京大学 | 一种具有镇痛作用的小分子肽及其特异性抗体 |
| CN114470197B (zh) * | 2022-02-16 | 2023-10-03 | 天津长和生物技术有限公司 | 低氧培养的hUCMSC联合NogoA抗体在脊髓损伤治疗中的应用 |
| WO2024041450A1 (zh) * | 2022-08-22 | 2024-02-29 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别Nogo-A的抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308573D0 (en) | 1983-03-29 | 1983-05-05 | British Nuclear Fuels Ltd | Filament impregnating/coating |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| JP2904918B2 (ja) | 1989-02-13 | 1999-06-14 | シェーリング アクチェンゲゼルシャフト | 新規血栓溶解剤 |
| WO2000005364A1 (en) * | 1998-07-22 | 2000-02-03 | Smithkline Beecham Plc | Protein similar to neuroendrocrine-specific protein, and encoding cdna |
| KR100828058B1 (ko) * | 2000-01-12 | 2008-05-09 | 예일 유니버시티 | Ｎｏｇｏ 수용체가 매개하는 축삭 성장의 차단 |
| CA2468733C (en) * | 2001-11-30 | 2013-06-11 | Biogen Idec Ma Inc. | Antibodies against monocyte chemotactic proteins |
| GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
| PL1711530T3 (pl) * | 2003-12-22 | 2010-01-29 | Glaxo Group Ltd | Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych |
-
2003
- 2003-09-19 GB GBGB0321997.9A patent/GB0321997D0/en not_active Ceased
-
2004
- 2004-09-16 AR ARP040103334A patent/AR045671A1/es unknown
- 2004-09-17 EP EP10176103A patent/EP2423225A3/en not_active Withdrawn
- 2004-09-17 NZ NZ545679A patent/NZ545679A/en not_active IP Right Cessation
- 2004-09-17 US US10/572,434 patent/US20090181023A1/en not_active Abandoned
- 2004-09-17 KR KR1020067005424A patent/KR20060119982A/ko not_active Application Discontinuation
- 2004-09-17 BR BRPI0414174A patent/BRPI0414174B8/pt not_active IP Right Cessation
- 2004-09-17 JP JP2006526602A patent/JP2007527232A/ja active Pending
- 2004-09-17 AU AU2004274164A patent/AU2004274164B2/en not_active Ceased
- 2004-09-17 MY MYPI2013003188A patent/MY161068A/en unknown
- 2004-09-17 MY MYPI20043786A patent/MY158078A/en unknown
- 2004-09-17 WO PCT/EP2004/010489 patent/WO2005028508A2/en active Application Filing
- 2004-09-17 CA CA2538725A patent/CA2538725C/en not_active Expired - Fee Related
- 2004-09-17 EP EP04765380A patent/EP1668033A2/en not_active Withdrawn
- 2004-09-17 PE PE2004000908A patent/PE20050949A1/es not_active Application Discontinuation
- 2004-09-17 RU RU2006112849/13A patent/RU2380377C2/ru active
- 2004-09-17 CN CNA2004800332675A patent/CN1878792A/zh active Pending
- 2004-09-17 EP EP10160905A patent/EP2248827A1/en not_active Withdrawn
- 2004-09-17 TW TW093128254A patent/TWI372060B/zh not_active IP Right Cessation
- 2004-09-17 SG SG200806933-8A patent/SG146660A1/en unknown
-
2006
- 2006-03-03 ZA ZA200601842A patent/ZA200601842B/en unknown
- 2006-03-06 IL IL174145A patent/IL174145A/en active IP Right Grant
- 2006-03-17 TN TNP2006000085A patent/TNSN06085A1/en unknown
- 2006-03-17 EC EC2006006431A patent/ECSP066431A/es unknown
- 2006-03-29 CO CO06031001A patent/CO5680457A2/es active IP Right Grant
- 2006-04-07 MA MA28921A patent/MA28088A1/fr unknown
- 2006-04-10 IS IS8404A patent/IS8404A/is unknown
- 2006-04-12 NO NO20061678A patent/NO20061678L/no not_active Application Discontinuation
-
2009
- 2009-01-22 AU AU2009200237A patent/AU2009200237B2/en not_active Ceased
- 2009-12-28 IL IL203007A patent/IL203007A/en active IP Right Grant
-
2010
- 2010-06-16 US US12/816,964 patent/US20110008334A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001756A1 (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| Reiter et al. | Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| PE20120622A1 (es) | Anticuerpos anti-vegf y sus usos | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| PE20141564A1 (es) | Moleculas de union para bcma y cd3 | |
| PE20090689A1 (es) | Anticuerpos del antagonista ox40 y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| PE20030104A1 (es) | Anticuerpos humanos para cd154 | |
| PE20091449A1 (es) | Proteinas de union a antigenos | |
| JP2018527903A (ja) | Ｇｄｆ１１結合タンパク質およびその使用 | |
| PE20140218A1 (es) | Composicion farmaceutica | |
| PE20091269A1 (es) | Moleculas de union al receptor ox40 humano | |
| PE20050925A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
| RU2018128215A (ru) | Антитела против mica | |
| CO6251370A2 (es) | Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma | |
| PE20120415A1 (es) | Anticuerpos anti-igf | |
| PE20060418A1 (es) | Anticuerpos antagonistas de il-17 | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
| CY1110848T1 (el) | Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση | |
| PE20020125A1 (es) | Moleculas de enlace a mcp-1 | |
| AR079458A2 (es) | Anticuerpo monoclonal quimerico que se une a cd45 | |
| PE20050949A1 (es) | Moleculas de union nogo-a | |
| PE20020871A1 (es) | Moleculas de enlace terapeuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |